Relapse Rate in the Real World Following Biologic Discontinuation in Psoriasis 真实世界中生物制剂停药后银屑病复发率

Across three of the four studies, roughly 8–9 out of 10 patients flared again after stopping their biologic. Even the IL-23 group, which many doctors think is longer-lasting, showed most relapses within a year. One study that mixed mainly IL-17 drugs saw a lower figure (about 1 in 2 relapsed by 6 months), but the authors only tracked that 6-month window, so the final total would likely be higher. Bottom line: biologics control psoriasis well while you take them, but stopping usually leads to a comeback fairly quickly.

除了一项主要观察 6 个月的数据外，其余三项研究显示停药后约 80–90 % 的患者会在一年内复发。即便是被认为“维持时间较长”的 IL-23 抑制剂，也有多数病人在 12 个月内复发。总体来看，生物制剂能有效控制银屑病，但一旦停药，大多数病人仍会较快地再次发作。

Reference

  1. Huang YH, Hung SJ, Lee CN, Wu NL, Hui RC, Tsai TF, Huang CM, Chiu HY. Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study. Am J Clin Dermatol. 2024 Nov;25(6):997-1008.
  2. Chiu HY, Hui RC, Tsai TF, Chen YC, Chang Liao NF, Chen PH, Lai PJ, Wang TS, Huang YH. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study. J Am Acad Dermatol. 2023 Jan;88(1):71-78.
  3. Huang S, Chen B, Qi Y, Duan X, Bai Y. Development and external validation of a prediction model for the risk of relapse in psoriasis after discontinuation of biologics. Front Med (Lausanne). 2024 Nov 26;11:1488096.
  4. Hsieh CY, Hsu FL, Tsai TF. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis. Dermatol Ther (Heidelb). 2024 Sep;14(9):2607-2620. doi: 10.1007/s13555-024-01229-6. Epub 2024 Jul 29. PMID: 39073712; PMCID: PMC11393235.